Company (Country/Symbol)

Company (Country/Symbol)

Type/Product Area

Terms/Details (Month)

Abgenix Inc. (ABGX)

Corixa Corp. (CRXA)

Research collaboration/Use of Abgenix's XenoMouse technology to discover and develop monoclonal antibodies against selected targets from Corixa's library of autoimmune disease, cancer and infectious disease

Six-year agreement covers three initial targets and up to six per year; each antibody eligible for clinical testing will be subject to a closed auction between the two companies for rights to development; the winning company will pay the bid amount in cash to the other company and will be responsible for all development expenses and decisions; the non-development company will receive a share of future product development milestones and a small royalty on any sales (3/00)

Affymetrix Inc.(AFFX)

InphoGene BioCom Inc.*

Development collaboration/InphoGene will use Affymetrix's GeneChip probe arrays to build an Internet-based commercial reference source for gene expression information relating to cardiopulmonary disease

InphoGene will market the databases to pharmaceutical and biotechnology companies for use alone or in combination with Gene-Chip probe arrays or any products compliant with the standards of the Genetic Analysis Technology Consortium; InphoGene will pay Affymetrix annual subscription fees; purchase probe arrays; related instrumentation and software; and, after certain milestones have been achieved, pay royalties to Affymetrix on subscription fees (4/00)

Affymetrix Inc. (AFFX)

NEN Life Science Products*

License/Use of Affymetrix's technology for low- and medium-density pre-spotted DNA arrays

NEN has been granted a non-exclusive worldwide license to manufacture, use and sell DNA arrays in the research field for gene expression analysis and comparative genomic hybridization with mechanically spotted arrays; the license does not apply to Affymetrix technology for light-directed synthesis; Affymetrix will receive undisclosed fees and royalty payments, and NEN will cooperatively promote Affymetrix's scanners and software (3/00)

AutoImmune Inc. (AIMM)

Subsidiary of Elan Corp. plc (Ireland; NYSE: ELN)

License/AutoImmune's rights to patent applications involving the treatment of Alzheimer's disease

AutoImmune will receive up to $7M in cash in a combination of up-front payments and contingent payments over the next three years; at the time the contingent payments are made, the buyer will receive warrants to purchase up to 0.75M shares of AutoImmune stock at the market price when the warrants were issued (3/00)

AVI BioPharma (AVII)

Gene Tools LLC*

License/In vitro diagnostic applications of AVI's Neugene antisense technology

AVI received $1M and additional undisclosed consideration from Gene Tools in exchange for an exclusive license (the companies' previous agreement was non-exclusive) (3/00)

AVI BioPharma (AVII)

SuperGen Inc. (SUPG)

Sales and marketing/AVI's therapeutic cancer vaccine, Avicine

SuperGen will make an up-front equity investment of $20M in a combination of cash and SuperGen stock; additional equity investments and milestone payments are contemplated that would make the total value of the pact in excess of $100M; SuperGen also will receive a warrant to purchase an additional 10% of AVI stock at a 300% premium the 4/4/00 closing price of $35.625 per share; the companies will share profits and development/regulatory costs in the U.S.; SuperGen will be responsible for U.S. marketing and sales, and AVI will be responsible for manufacturing; companies will jointly determine development strategy for the international marketplace and share all profits; SuperGen paid $5M in 12/99 for the right to negotiate a marketing deal (4/00)

Axon Instruments Inc.*

Motorola BioChip Systems (unit of Motorola Inc.; NYSE:MOT)

Distribution of agreement/distribution of Axon's GenePix 4000A microarray scanner as part of Motorola's bioarray solution

ND (4/00)

BioQuest Inc. (Pink Sheets: HIVX)

Biovector Therapeutics SA* (France)

Evaluation and development/Therapeutic and potentially protective HIV vaccine combining BioQuest's "cocktail" of peptides from the HIV protein envelope and Biovector's technology for inducing immune responses using lipopeptide constructs to deliver cytotoxic T lymphocyte-inducing antigens through the major histocompatibility Class 1 pathway

Biovector will pay milestones and royalties (4/00)

Biosyntech (OTC BB:BSYI)

Viragen Inc. (OTC BB:VRGN) and Viragen Europe (OTC BB: VERP)

Research collaboration/Use of Biosyntech's BST-Gel as a sustained-release system for Viragen's Omniferon (natural, multi-subtype alpha interferon in Phase II trials for hepatitis C)

ND (3/00)

BTG International Ltd. (subsidiary of BTG plc [UK; LSE: BGC])

CeNeS Drug Delivery Ltd. (UK; subsidiary of CeNeS Pharmaceuticals plc)

License/Use of BTG's hydrogel technology for Moraxen, CeNeS' 24-hour sustained-release morphine product recently submitted for marketing approval in the UK

Extension of licenses from BTG; new arrangement gives CeNeS worldwide rights to apply the technology to any molecule other than prostaglandins and medicinal products for oromucosal use; BTG has waived rights to future milestone and royalty payments on the technology and will receive #2.02M (US$3.2M) for extending the term; BTG will pay #1.02M (US$1.6M) for 1.02M ordinary shares of CeNeS, and will buy an additional #1M (US$1.6M) worth of shares on 12/31/00; BTG will buy stock in two additional tranches of #1M (US$1.6M) apiece upon CeNeS' reaching certain milestones, and CeNeS will make two further payments of #1M each to BTG upon reaching those same milestones

British Biotech (UK; BBIOY)

DevCo Pharmaceuticals Ltd.* (UK)

Development/Use of British Biotech's lexipafant, for the prophylaxis of certain serious neurological and renal complications associated with cardiac surgery

DevCo gains exclusive rights to develop, manufacture and sell lexipafant for the treatment of human disease other than in the fields of oncology and ophthalmology; DevCo will undertake all the development, and, if lexipafant is brought to market, pay British Biotech royalties (3/00)

Caliper Technologies Corp. (CALP)

Millennium Pharmaceuticals Inc. (MLNM)

Technology access and application development/Use of Caliper's LabChip microfluidic high-throughput technology platform

Collaboration provides for Millennium to subscribe to Caliper's Technology Access Program, as well as for joint investment in and development of novel LabChip applications focused on genomics and other areas of mutual interest (3/00)

CareScience*

British Biotech (UK; BBIOY)

Development/Creation of a web-based analytical tool for acquiring, managing and evaluating clinical data in the field of oncology (an "Oncology Extranet")

British Biotech will have exclusive use of the Oncology Extranet for a limited period following development; thereafter, Care-Science will market and sell the product with royalties to British Biotech; British Biotech will provide CareScience with development and service fees of US$1.5M over the first three years of the collaboration, and will have rights to purchase CareScience common stock under certain conditions; British Biotech will provide specialist assistance to define, test and validate the product (4/00)

CuraGen Corp. (CRGN)

COR Therapeutics Inc. (CORR)

Research collaboration/Application of CuraGen's functional genomics technologies to cardiovascular disease; the companies will use CuraGen's PathCalling proteomics technology and bio-informatics systems to create an annotated database of protein-protein interactions derived from cardiovascular endothelial cells

Expansion of 5/99 agreement to discover additional drug targets, as well as to offer functional information and validation of previously discovered targets (3/00)

CuraGen Corp. (CRGN)

Genentech Inc. (NYSE:DNA)

Research collaboration/Application of CuraGen's high-throughput functional genomic technologies and disease expertise to advance discovery of protein therapeutics and antibodies

Renewal of 1997 collaboration for a minimum of 2.5 years; Genentech will pay CuraGen research fees for access to technologies and databases; Genentech retains rights to license, develop and market therapeutics derived from these efforts; CuraGen also will receive milestone payments and royalties on sales (4/00)

CytoTherapeutics (CTII)

Genentech Inc. (NYSE:DNA)

Resolution of legal dispute/Dispute relates to 1996 collaborative agreement centering on CytoTherapeutics' former encapsulated cell technology

Under certain circumstances, CytoTherapeutics was obligated to redeem a portion of the stock that Genentech had bought as part of the agreement; under the settlement agreement, CytoTherapeutics is relieved of the obligation (3/00)

Cytovia Inc.*

Axys Pharmaceuticals Inc. (AXPH)

Research collaboration/Use of Axys' combinatorial chemistry library, medicinal chemistry, preclinical and clinical development strengths with Cytovia's high-throughput screening technologies, and molecular and cellular biology

Each company will fund its own research as part of the collaboration; Axys also is making an up-front equity investment in Cytovia; Axys will have the first right to develop any drug candidates that emerge and will pay Cytovia a royalty on any sales; Cytovia may exercise a profit-share option at a predetermined point during development in lieu of royalties; if exercised, Cytovia will share equally in profits and costs; if Axys chooses not to develop a drug candidate, Cytovia will have the right to do so, with Axys having the right to either profit sharing or royalties (3/00)

Digital Gene Technologies Inc.*

Elan Corp. plc (Ireland; NYSE: ELN)

Partnership-based research collaboration/Use of Digital Gene's TOGA (Total Gene Expression Analysis) technology in Elan's Alzheimer's and Parkinson's disease models; TOGA also will be used to investigate and develop new drug delivery mechanisms

Partnership will provide at least $58M in support; partners will share ownership of products that emerge; during the first two years of the agreement, Elan may elect to expand the covered research to include two additional central nervous system disease fields, on comparable terms; Elan also is making a $10M equity investment in Digital Gene Technologies (4/00)

Dyax Inc.*

Human Genome Sciences Inc. (HGSI)

Research collaboration and license/Use of Dyax's phage display technology to develop an unlimited number of therapeutic and diagnostic products that HGS may choose to sell itself or outlicense

Over the next several years, HGS will pay Dyax $16M for licenses and committed research support; HGS also will provide milestone and royalty payments to Dyax for products HGS develops and will share revenue from outlicensing (3/00)

Dynavax Technologies Corp.*

Triangle Pharmaceuticals Inc. (VIRS)

License/Use of Dynavax's immunostimulatory DNA sequences for the treatment of HIV and hepatitis C virus; initial focus is on completing late-preclinical studies in hepatitis B

Triangle will receive an exclusive worldwide license to Dynavax's immunostimulatory sequences for the treatment of HIV in the unlinked form only and prophylaxis of hepatitis B and C in both the unlinked and antigen-linked forms; in return, Triangle will purchase $2M worth of Dynavax preferred stock, and will provide non-contingent research funding, make contingent development milestone payments and pay royalties on sales (4/00)

Epidauros Biotechnologie AG (Germany)

MWG Biotech AG (Germany; Neuer Markt:NWV)

Development collaboration/Development of a pharmacogenomic chip to be used in clinical trials and at the bedside

MWG will pay DM10M (US$4.9M) up front, along with milestone and technology access fees; Epidauros is responsible for validation in more than 500 patients (4/00)

Exiqon AS* (Denmark)

Proligo LLC* (joint venture between SKW Trostberg AG [Germany] and Gilead Sciences Inc. [GILD])

Commercialization/Sale of Exiqon's nucleic acid analog technology (oligonucleotides and monomers)

Proligo will have the right to manufacture and sell the oligonucleotides and monomers to third parties worldwide, while Exiqon will retain

Gene-Cell Inc. (OTC BB:GCLL)

Athersys Inc.*

Research collaboration/Use of Gene-Cell's automated micro-injection technology to deliver Athersys' Synthetic Microchromosome vectors into human stem cells

ND (3/00)

Genome Therapeutics Corp. (GENE)

Compugen Ltd.* (Israel)

Commercialization/Incorporation of Genome Therapeutics' PathoGenome database of microbial genetic information into Compugen's LabOnWeb.com Internet portal

Compugen gains exclusive rights to make PathoGenome available over the Internet; companies will share revenues generated from customer use (4/00)

Gilead Sciences Inc. (GILD)

EyeTech Pharmaceuticals Inc.*

License/Therapeutic uses of Gilead's aptamer NX1938, an inhibitor of vascular endothelial growth factor (known to play a role in ophthalmic diseases)

EyeTech paid an up-front licensing fee of $7M, and Gilead is entitled to additional cash payments of up to $25M based upon achievement of development milestones; EyeTech will be responsible for all R&D costs and will pay Gilead royalties on sales; EyeTech also issued Gilead a warrant to purchase 0.83M shares (at $6 each) of convertible preferred stock (4/00)

Gemini Genomics plc*

CuraGen Corp. (CRGN)

Research collaboration/Association of CuraGen's human genetic variants with disease traits derived from Gemini's database of clinical populations, in order to validate genes and genetic variants that are associated with complex diseases

Renewable two-year collaboration; CuraGen will apply the information discovered to drug development and pharmacogenomics (4/00)

Genzyme Transgenics Corp. (GZTC)

Centocor Inc. (subsidiary of Johnson & Johnson; NYSE:JNJ)

Production agreement/Production of a Centocor monoclonal antibody using Genzyme Transgenics' technology for antibody production in the milk of transgenic goats

Expansion of 12/98 agreement to include a second antibody; Genzyme Transgenics will provide the milk-expressed antibody to Centocor in exchange for undisclosed fees and milestone payments (3/00)

Immunicon Corp.*

Therakos Inc.*

Research collaboration/Exploration of applications of Immunicon's magnetic separation technology with Therakos' cell therapy technology in the field of extracorporeal photoimmune therapy

ND

Intergen Co.*

Amersham Pharmacia Biotech Inc.

License/AP Biotech will use Intergen's Amplifluor to enable detection in its Rolling Circle Amplification technology for ultra-sensitive, high-throughput detection of single nucleotide polymorphisms

Licensing agreement (3/00)

Medarex Inc. (MEDX)

Raven Biotechnologies Inc.*

Research collaboration/Use of Medarex's HuMAb Mouse technology to develop fully human antibodies against multiple Raven antigens

Medarex could receive research payments, license fees and milestone payments, as well as royalties on sales (3/00)

Medarex Inc. (MEDX)

Genmab A/S* (Denmark; Medarex joint venture with BankInvest)

Research collaboration/Use of Medarex's HuMAb Mouse technology to develop fully human antibodies

Expanded agreement gives Genmab the ability to create an unlimited number of antibody products using HuMAb Mouse (4/00)

Medarex Inc. (MEDX)

Coulter Pharmaceutical (CLTR)

Research collaboration and license option/Use of Medarex's HuMAb Mouse technology to generate fully human monoclonal antibodies against a number of specific target antigens

Coulter will have the option to obtain exclusive commercial rights to the antibodies; in return, Medarex could receive R&D payments, license fees and milestone payments, as well as royalties on sales (4/00)

MorphoSys AG (Germany; Neuer Markt: MORG)

Millennium Pharmaceuticals Inc. (MLNM)

Research collaboration/MorphoSys will apply its HuCAL technology to generate human antibodies for a new target molecule in inflammatory disorders provided by Millennium; deal covers up to six additional targets

Expansion of 8/98 collaboration between MorphoSys and LeukoSite (since acquired by Millennium); under the agreement, MorphoSys receives an up-front payment and R&D funding, as well as milestone payments and royalties on sales (3/00)

NeuralStem BioPharmaceuticals Ltd.*

Gene Logic Inc. (GLGC)

Equipment purchase, research collaboration/ NeuralStem will use Gene Logic's GeneExpress database for drug discovery in central nervous system diseases; Gene Logic gains access to NeuralStem's repository of highly characterized stem cells for gene expression analysis and will include the resulting data in GeneExpress

NeuralStem purchased a GeneExpress module to become the fourth commercial customer of the database; additional terms ND (4/00)

Orquest Inc.*

Biopharm GmbH* (Germany)

Research and development collaboration/development of products that combine Biopharm's MP52 recombinant bone morphogenic protein (a growth factor) and Orquest's materials and know-how for developing and assembling combinations of growth factors and matrices

Companies will pool their technologies to develop a portfolio of products that promote the growth of new tissues lost to degenerative disease or injury; the first product, HealosMP52, is expected to enter clinical studies shortly in the U.S. and Europe for spinal fusion in collaboration with Sulzer Spine-Tech (4/00)

PE Biosystems (NYSE:PEB)

Visible Genetics Inc. (VGIN)

License/Use of PE technology to manufacture and sell DNA sequencing instruments, as well as clinical sequencing kits to run on the instruments; development of diagnostics based on the technology

Agreement resolves a patent dispute PE filed against Visible; Visible will pay a $25M licensing fee over four years, as well as royalties on sales (4/00)

Pharmacopeia Inc. (PCOP)

PE Biosystems Group (NYSE:PEB) and BD Biosciences (unit of Becton, Dickinson and Co. (NYSE:BDX)

License/Incorporation of Pharmacopeia's high-throughput screening technology based on confocal microscopy

PE and BD Biosciences obtained a co-exclusive license, and will co-develop instrumentation which can deploy the technology in connection with their high-throughput screening systems for sale to third parties; Pharmacopeia received an up-front payment from PE and BD Biosciences and will receive royalties on sales by the companies and their sublicensees; in addition, PE Biosystems and BD Biosciences will develop and deliver to Pharmacopeia a custom instrument for ultra-high-throughput screening for use internally at Pharmacopeia (4/00)

Procyon Biopharma Inc. (Canada; CDNX: PBP)

IMI International Medical Innovations Inc. (CDN:IMIN)

Development and commercialization/Colorectal cancer screening tests

Companies signed a letter of intent to consolidate their colorectal cancer tests, with IMI to lead development, clinical trials and commercialization efforts; Procyon will provide scientific support, contribute funding and share pro rata in the initiative's revenues; joint initiative will be housed within IMI

Protein Design Labs Inc. (PDLI)

Tanox Inc. (TNOX)

License/Use of PDL's humanization technology for monoclonal antibodies

Tanox will pay a $2.5M up-front fee for rights to obtain a non-exclusive license for up to four Tanox antibodies; up-front payment was based on PDL's $4M standard fee, less a credit of $1.5M for a fee paid previously for an antibody, which has been incorporated into the new agreement; upon exercise of a license for a particular antibody, Tanox will pay an additional fee, annual maintenance fees and royalties on sales (4/00)

Quantum.Dot Corp.*

Genentech Inc. (NYSE:DNA)

Evaluation/Genentech will evaluate for use in assays Quantum Dot's Qdot Nanocrystal technology, which consists of molecule-size semiconductors that light up like LEDs and enable sensitive detection of DNA and proteins

Genentech joins Quantum Dot's Technology Access Program as a charter member; during 2000, Qdot Nanocrystals will be available only to participants in the access program and to select academic centers of excellence (4/00)

Sequenom Inc. (SQNM)

Methexis Genomics NV* (Belgium)

Equipment purchase, research collaboration/Companies will use combined technologies to discover and assess genetic variations relevant to both medical and agricultural applications

Methexis purchased Sequenom's MassAR-Ray system for differential sequencing to discover genetic variations; financial details of the collaboration were undisclosed (3/00)

Shearwater Polymers Inc.*

Sensus Drug Development Corp.*

License/Use of Shearwater's polyethylene glycol technology (PEGylation) to develop an improved formulation of Sensus Somavert, a genetically modified form of human growth hormone

Shearwater will receive substantial up-front payments, rights to manufacture the polyethylene glycol formulation and a share of downstream revenues (4/00)

Sentron Medical Inc.*

Genzyme Tissue Repair (GZTR)

License/Use of Sentron's autologous chondrocyte graft technology to grow preformed cartilage tissue on a two-dimensional surface

Genzyme gains an exclusive worldwide license and related intellectual property rights and will provide Sentron up-front and milestone payments, the most significant of which are tied to commercialization of the technology; payment will be made either in equity in Genzyme Tissue Repair or a combination of equity and cash; Genzyme also will pay royalties (4/00)

SIGA Technologies Inc. (SIGA)

New England Biolabs*

Research collaboration/Combines SIGA's vaccine delivery technology with schistosomiasis antigens identified by NEB scientists

Research will be carried out at SIGA Research Labs, the biotechnology division of SIGA, and at NEB; companies also announced successful outcome of a joint research project using SIGA's vaccine delivery technology for the expression of self-cleaving programs called inteins (3/00)

SkyePharma plc (UK; SKYE)

Amgen Inc. (AMGN)

Evaluation/Use of SkyePharma's DepoFoam sustained-release injectable delivery system with an undisclosed Amgen product

Upon signing the contract, SkyePharma made a final contingent payment to former shareholders in DepoTech, which SkyePharma acquired 3/99; each shareholder will receive an additional 0.79 SkyePharma American Depositary Shares for every 10 shares of DepoTech owned; shares are worth #13.3M (US$21.3M) at the 3/31/00 closing price (4/00)

Synergy Pharmaceuticals Inc.*

United Therapeutics Corp. (UTHR)

License, acquisition option/Rights to antiviral drug compounds designed to prevent three-dimensional folding of all viruses (including hepatitis B and C, dengue and Japanese encephalitis) that bud from the endoplasmic reticulum within cells

United Therapeutics licensed the compounds and purchased 15% of Synergy, with an option to acquire the remainder of the company (3/00)

Techniclone Corp. (TCLN)

Scotia Pharmaceuticals Ltd. (UK; LSE: SOH)

License/Use of Techniclone's Vascular Targeting Agent technology in photodynamic therapy applications

Companies signed a binding letter of intent for exclusive worldwide rights; Techniclone will receive a licensing fee, milestone payments and royalties on sales (4/00)

V.I. Technologies Inc. (Vitex; VITX)

Amersham Pharmacia Biotech (the life sciences business of Nycomed Amersham plc [LSE: NAM]

Marketing and distribution agreement/Vitex's Inactine pathogen inactivation technology for manufacturers of biopharmaceuticals and transgenic products and to plasma fractionators

AP Biotech will exclusively market and distribute the technology in the covered areas; Vitex will receive an up-front cash payment, with the potential to receive considerably more in milestone payments and research support, as well as ongoing royalties on sales and use of the technology by AP Biotech customers; companies also will collaborate on development and refinement of the technology; Vitex retains all rights to use Inactine for viral inactivation in blood components such as red cells, platelets and plasma (4/00)

Xenogenics Corp. (majority-owned subsidiary of Multi-Cell Associates Inc.*)

Exten Industries Inc.*

Supply agreement/MultiCell will supply Exten a unique engineered porcine liver cell line and optimize the interface between this cell line and Exten's SybiolR, a bioartificial liver

ND (3/00)

Notes:

# This chart does not include any agreements that involve agricultural product development.

* Private companies are indicated with an asterisk.

Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

AMEX =American Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange